US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
- Popular podcaster and influencer Joe Rogan has been accused of cashing in on brain health supplement2024-05-22
Excessive nitrogen fertilizer yields less attractive apples: research
(Xinhua) 16:50, January 04, 2024JINAN, Jan. 4 (Xinhua) -- Waxiness significantly influences the lust2024-05-22Nation powering ahead on renewables
By Zheng Xin (China Daily) 08:13, December 25, 2023A view of a wind farm off the coast of Rudong cou2024-05-22- (Xinhua) 09:30, March 20, 2024A press conference on leveraging Beijing's strategic role as the natio2024-05-22
Judge blocks Biden administration from enforcing new gun sales background check rule in Texas
AUSTIN, Texas (AP) — A federal judge has blocked the Biden administration from enforcing a new rule2024-05-22Cultural exchange activities on BRICS cooperation held in South Africa
(Xinhua) 09:24, August 22, 2023JOHANNESBURG, Aug. 21 (Xinhua) -- A series of cultural and people-to-2024-05-22
atest comment